Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $11,265,557 | $4,030,055 | $1,934,598 | $3,421,711 |
| - Cash | $251,359 | $55,067 | $57,604 | $56,805 |
| + Debt | $11,872 | $11,863 | $7,842 | $1,476 |
| Enterprise Value | $11,026,070 | $3,986,851 | $1,884,836 | $3,366,382 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$26,669 | -$29,244 | -$26,864 | -$23,261 |
| % Margin | – | – | – | – |
| Net Income | -$26,925 | -$26,732 | -$24,063 | -$19,980 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.71 | -0.75 | -0.12 | -0.1 |
| % Growth | 5.3% | -525% | -20% | – |
| Operating Cash Flow | -$17,465 | -$25,070 | -$20,237 | -$14,446 |
| Capital Expenditures | -$134 | -$22 | -$291 | -$226 |
| Free Cash Flow | -$17,599 | -$25,092 | -$20,528 | -$14,672 |